List of Excipients in API glecaprevir and pibrentasvir
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing glecaprevir and pibrentasvir
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AbbVie Inc | MAVYRET | glecaprevir and pibrentasvir | 0074-2625 | COPOVIDONE K25-31 | 2036-12-24 |
| AbbVie Inc | MAVYRET | glecaprevir and pibrentasvir | 0074-2625 | CROSCARMELLOSE SODIUM | 2036-12-24 |
| AbbVie Inc | MAVYRET | glecaprevir and pibrentasvir | 0074-2625 | FERRIC OXIDE RED | 2036-12-24 |
| AbbVie Inc | MAVYRET | glecaprevir and pibrentasvir | 0074-2625 | HYPROMELLOSE 2910 | 2036-12-24 |
| AbbVie Inc | MAVYRET | glecaprevir and pibrentasvir | 0074-2625 | LACTOSE MONOHYDRATE | 2036-12-24 |
| AbbVie Inc | MAVYRET | glecaprevir and pibrentasvir | 0074-2625 | POLYETHYLENE GLYCOL 3350 | 2036-12-24 |
| AbbVie Inc | MAVYRET | glecaprevir and pibrentasvir | 0074-2625 | PROPYLENE GLYCOL MONOCAPRYLATE | 2036-12-24 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for glecaprevir and pibrentasvir
Excipient focus: COPOVIDONE K25-31
glecaprevir and pibrentasvir drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
glecaprevir and pibrentasvir drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
glecaprevir and pibrentasvir drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
glecaprevir and pibrentasvir drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
glecaprevir and pibrentasvir drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
glecaprevir and pibrentasvir drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL MONOCAPRYLATE
glecaprevir and pibrentasvir drug variants containing PROPYLENE GLYCOL MONOCAPRYLATE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing PROPYLENE GLYCOL MONOCAPRYLATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
glecaprevir and pibrentasvir drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
glecaprevir and pibrentasvir drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
glecaprevir and pibrentasvir drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: VITAMIN E POLYETHYLENE GLYCOL SUCCINATE
glecaprevir and pibrentasvir drug variants containing VITAMIN E POLYETHYLENE GLYCOL SUCCINATE
| Company | Ingredient | NDC |
|---|---|---|
| AbbVie Inc | glecaprevir and pibrentasvir | 0074-2625 |
| >Company | >Ingredient | >NDC |
glecaprevir and pibrentasvir drug variants not containing VITAMIN E POLYETHYLENE GLYCOL SUCCINATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
